<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01531309</url>
  </required_header>
  <id_info>
    <org_study_id>CAGO178C2102</org_study_id>
    <nct_id>NCT01531309</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of AGO178 in Participants With Liver Impairment</brief_title>
  <official_title>An Open-Label, Parallel-Group Study to Compare the Pharmacokinetics, Safety and Tolerability of a Single Sublingual 1 mg Dose of AGO178 in Subjects With Mild and Moderate Hepatic Impairment With That in Matched Healthy Control Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Servier</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      AGO178 was developed for the treatment of depression. A new formulation is being tested in&#xD;
      the present study: a tablet to be placed and dissolved under the tongue (sublingual tablet).&#xD;
      The goal of this trial was to study the pharmacokinetics of agomelatine given as sublingual&#xD;
      tablet in participants with liver impairment and to compare the results to those of healthy&#xD;
      volunteers who receive the same treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 8, 2011</start_date>
  <completion_date type="Actual">September 2, 2011</completion_date>
  <primary_completion_date type="Actual">September 2, 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of AGO178</measure>
    <time_frame>Predose, 2 minute (min) , 5 min , 10 min, 20 min, 30 min, 45 min, 1 hour (h), 1.5h, 2h, 3h, 4h, 6h, 12h, 24h, 36h Post dose</time_frame>
    <description>Blood samples will be collected at various time points on day 1 and day 2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Curve (AUC) of AGO178</measure>
    <time_frame>Predose, 2 min , 5 min , 10 min, 20 min, 30 min, 45 min, 1h, 1.5h, 2h, 3h, 4h, 6h, 12h, 24h, 36h Post dose</time_frame>
    <description>Blood samples will be collected at various time points on day 1 and day 2</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events</measure>
    <time_frame>Baseline and Day 8</time_frame>
    <description>Adverse events will be based on evaluation of physical signs, electrocardiograms and clinical laboratory assessments (clinical chemistry, hematology, urinalysis).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Hepatic Impairment</condition>
  <arm_group>
    <arm_group_label>Mild Hepatic Impaired Participants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mild hepatic impaired participants will receive a single sublingual dose of AGO178, 1 milligram (mg) on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moderate Hepatic Impaired Participants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Moderate hepatic impaired participants will receive a single sublingual dose of AGO178, 1 mg on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Participants Matched by Aged, Gender and Body Mass Index (BMI)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy participants matched by aged, gender and BMI will receive a single sublingual dose of AGO178, 1 mg on Day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AGO178</intervention_name>
    <description>AGO178 is administered as a sublingual tablet.</description>
    <arm_group_label>Healthy Participants Matched by Aged, Gender and Body Mass Index (BMI)</arm_group_label>
    <arm_group_label>Mild Hepatic Impaired Participants</arm_group_label>
    <arm_group_label>Moderate Hepatic Impaired Participants</arm_group_label>
    <other_name>Agomelatine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants with liver disease confirmed within 3 months of screening.&#xD;
&#xD;
          -  If liver impairment is caused by alcohol use, participants must have abstained from&#xD;
             alcohol use within 3 months of study start.&#xD;
&#xD;
          -  Participants must satisfy criteria for Child- Pugh Class A or B.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of other investigational drugs at the time of enrollment, or within 30 days or 5&#xD;
             half-lives of enrollment, whichever is longer.&#xD;
&#xD;
          -  Pregnant or nursing (lactating) women.&#xD;
&#xD;
          -  Women of child-bearing potential, defined as all women physiologically capable of&#xD;
             becoming pregnant, unless using effective contraception during the study.&#xD;
&#xD;
          -  Donation or loss of 400 millilitres (mL) or more of blood within eight (8) weeks prior&#xD;
             to initial dosing.&#xD;
&#xD;
          -  Significant illness within the two weeks prior to the dosing.&#xD;
&#xD;
          -  Participants with Child-Pugh alterations due to a non-liver disease (e.g. cancer or&#xD;
             treatment related weight loss).&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Orlando Clinical Research Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>February 3, 2012</study_first_submitted>
  <study_first_submitted_qc>February 8, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 10, 2012</study_first_posted>
  <last_update_submitted>May 6, 2021</last_update_submitted>
  <last_update_submitted_qc>May 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Liver impairment</keyword>
  <keyword>Major Depression Disorder</keyword>
  <keyword>Sublingual tablet</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>S 20098</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

